Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban pharmacokinetics in short bowel syndrome patients requiring long-term parenteral nutrition
2024-512061-14-00Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apixaban in short bowel syndrome (SBS) (5 cohorts), sponsored by UZ Leuven. Primary endpoint: Difference in apixaban peak level after single-dose administration. Started Oct 2021; status: completed.
02
Drugs
apixaban
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2024-512061-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512061-14-00.